Pancreas Cancer | LAP07
A randomised multicentre phase III study in patients with locally advanced adenocarcinoma of the pancreas; gemcitabine with or without chemoradiotherapy and with or without erlotinib.
Schema
Summary
For patients with pancreatic cancer, surgery to remove the entire tumor is the only potentially curative treatment. However, many patients have tumors that are localized but cannot be removed by surgery because the tumor is near a large blood vessel or joined to the stomach or bowel. These patients are generally treated with chemotherapy. Even with chemotherapy, their prognosis is very poor. It is not clear to doctors and researchers whether additional treatment with radiotherapy is beneficial. It is also unknown whether the newer targeted (antibody) type treatments are useful.
LAP07 is an international trial led by Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) a French collaborative research group. It will test whether a combination of chemotherapy and radiotherapy is better than chemotherapy alone in patients with localized but inoperable pancreatic cancer. It will also investigate the possible role of the newer antibody type drugs. Investigators will assess whether survival is improved with the addition of radiotherapy and the newer drugs.
